By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    headphones can create health problems
    The Harmful Health Effects of Using Headphones
    September 24, 2021
    Headache causes
    4 Causes Of Headache You Probably Didn’t Know About
    December 28, 2021
    follow these steps to recover from your injury
    What Steps Should You Take to Recover More Quickly from an Injury?
    April 12, 2022
    Latest News
    How Platform As A Service (Paas) Tool Can Be Used To Develop Software For Healthcare Service?
    December 11, 2023
    Managing Your Health After a Worksite Accident
    December 10, 2023
    Biohazard Cleanup: The Importance of Proper Disposal and Containment
    December 2, 2023
    Medicare Helps Seniors, and People with Disabilities & ESRD
    November 27, 2023
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Journalists Decry WH Decision to Pull Physicians’ Database
    September 16, 2011
    End of Life Care: The Feeding Tube Frenzy
    March 18, 2012
    physician care
    High Reliability Boot Camp: Preparing for Zero Preventable Harm
    May 23, 2013
    Latest News
    Child Protection Laws Safeguard Children from Abuse and Neglect
    December 11, 2023
    Exploring the Crucial Role of a CNA in Healthcare
    December 11, 2023
    The Role Of Second Opinions In Medical Errors
    December 10, 2023
    Urgent Care in Downers Grove: Meeting Community Health Care Needs
    December 10, 2023
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease
Share
Sign In
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Have an existing account? Sign In
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Public Health > Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease
Public Health

Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease

HerinaAyot
Last updated: 2017/09/09 at 8:59 PM
HerinaAyot
Share
2 Min Read
SHARE

Anavex Life Sciences Corp., ( OTCBB: AVXL) a publicly traded pharmaceutical company engaged in the discovery and development of novel drug candidates for the treatment of neurological diseases and cancer, recently announced that its clinical trial application for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program, Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73. While Alzheimer’s disease is most common in people over the age of 65, it can strike adults of any age irrespective of their gender, background or socioeconomic status. According to the Alzheimer’s Association an estimated 5.3 million Americans are currently living with Alzheimer’s disease. The number of Americans aged 65 and over with Alzheimer’s is estimated to reach 7.7 million in 2030. By 2050, between 11 million and 16 million Americans over 65 are expected to have Alzheimer’s disease. ANAVEX 2-73 is the first of a new class of wholly owned compounds that act through sigma-1 receptor agonism as well as muscarinic and cholinergic effects and modulation of endoplasmic reticulum stress to trigger a series of intracellular effects thought to modify ion channel signaling at the mitochondrial level. It is the first of a new class of oral, disease-modifying drugs being studied to potentially treat Alzheimer’s disease itself, versus treating its symptoms. The Phase I clinical trial of ANAVEX 2-73 will be carried out in collaboration with ABX-CRO and the University of Dresden in Germany.

TAGGED: Alzheimers

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
HerinaAyot September 9, 2017 March 25, 2011
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Response to Austin Frakt
Next Article Antibiotic Resistant Superbug Appears in California Hospitals

Stay Connected

1.5k Followers Like
4.5k Followers Follow
2.8k Followers Pin
136k Subscribers Subscribe

Latest News

walking safely
Walking Safety Tips to Help Pedestrians Minimize Injuries
News December 11, 2023
seasonal depression
4 Ways to Get Ahead of Winter Depression
Mental Health December 11, 2023
child safety laws
Child Protection Laws Safeguard Children from Abuse and Neglect
Policy & Law December 11, 2023
Demystifying Healthcare Software
How Platform As A Service (Paas) Tool Can Be Used To Develop Software For Healthcare Service?
Health December 11, 2023

You Might also Like

healthcare influencers
Public Health

The Impact of Health Influencers on Public Health

July 18, 2023
Health carePublic Health

Do You Need Life Insurance? What Does It Cover?

December 23, 2022

Do I Qualify for Social Security Disability Benefits if I Got Injured on My Way to Work?

August 23, 2022
Right Medicare Supplement Plan
Health carePublic Health

What If You Need Emergency Care and Don’t Have Insurance?

February 15, 2022
Subscribe

Subscribe to our newsletter to get our newest articles instantly!

Follow US
© 2008-2023 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Lost your password?